You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

EGFR amplification

Showing 1 - 25 of 2,237
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Solid Tumor, EGFR Amplification Trial in Tianjin (Nimotuzumab)

Recruiting
  • Solid Tumor
  • EGFR Amplification
  • Tianjin, Tianjin, China
    Tianjin Medical University Second Hospital
Aug 28, 2023

NSCLC Trial (HS-10241+ Almonertinib, Pemetrexed + Cisplatin /Carboplatin)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • HS-10241+ Almonertinib
  • Pemetrexed + Cisplatin /Carboplatin
  • (no location specified)
Oct 29, 2023

Pneumonia, Viral, COVID-19 Pneumonia, EGFR Amplification Trial in Bursa (None involvement)

Recruiting
  • Pneumonia, Viral
  • +2 more
  • None involvement
  • Bursa, Eyalet/Yerleşke, Turkey
  • +1 more
Mar 19, 2022

Esophageal Squamous Cell Carcinoma Trial in Beijing (Afatinib, Toripalimab)

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma
  • Beijing, Beijing, China
    Peking University Cancer Hospital and Institute
Jul 11, 2021

Advanced Malignant Solid Tumor, EGFR Gene Amplification, EGFR Gene Mutation Trial in Houston (Everolimus, Neratinib,

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +9 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 25, 2022

Recurrent/Advanced Gastric Cancer Trial in Seoul (Chemotherapy)

Not yet recruiting
  • Recurrent/Advanced Gastric Cancer
  • Seoul, Korea, Republic of
    Yonsei University Health System, Severance Hospital
Aug 22, 2022

Head Neck Cancer, Advanced Cancer, Metastatic Cancer Trial in Bordeaux, Lyon, Nice (Abemaciclib)

Recruiting
  • Head and Neck Cancer
  • +2 more
  • Bordeaux, France
  • +2 more
Jul 22, 2022

Glioblastoma, Brain Tumor, Recurrent Trial in Spain (PF-299804 (Dacomitinib))

Completed
Has Results
  • Glioblastoma
  • Brain Tumor, Recurrent
  • PF-299804 (Dacomitinib)
  • Badalona, Barcelona, Spain
  • +11 more
Jul 2, 2021

Gastric Cancer, Cetuximab, Nimotuzumab Trial in Shanghai (EGFR antibody and Chemotherapy, Chemotherapy)

Recruiting
  • Gastric Cancer
  • +2 more
  • Shanghai, China
    Department of Medical Oncology, Shanghai Changzheng Hospital
Dec 28, 2020

NSCLC Trial in Japan, Korea, Republic of, Singapore (capmatinib, pemetrexed, cisplatin)

Terminated
  • Carcinoma, Non-Small-Cell Lung
  • Kashiwa, Chiba, Japan
  • +3 more
Jan 31, 2023

Lung Non-Small Cell Carcinoma Trial (Amivantamab, Biospecimen Collection, Computed Tomography)

Not yet recruiting
  • Lung Non-Small Cell Carcinoma
  • Amivantamab
  • +3 more
  • (no location specified)
Oct 30, 2023

Esophageal Squamous Cell Carcinoma Trial in Beijing (Z650)

Active, not recruiting
  • Esophageal Squamous Cell Carcinoma
  • Beijing, Beijing, China
    Chinese PLA General Hospital, the Fifth Medical Center
Mar 17, 2021

Safety Trial in GuangZhou (Almonertinib combine with Pyrrolitinib)

Recruiting
  • Safety
  • Almonertinib combine with Pyrrolitinib
  • GuangZhou, Guang Dong, China
    Sun Yat-sen University Cancer Center
Mar 4, 2021

Glioblastoma Trial (CM93)

Not yet recruiting
  • Glioblastoma
  • (no location specified)
Jun 17, 2021

Negative T790M Mutation and Met Amplification Trial in Beijing (Glumetinib)

Unknown status
  • Negative T790M Mutation and Met Amplification
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Apr 7, 2020

Esophageal Squamous Cell Carcinoma Trial in Beijing (Afatinib)

Unknown status
  • Esophageal Squamous Cell Carcinoma
  • Beijing, Beijing, China
    Peking University Cancer Hospital and Institute
Jun 9, 2019

Brain Tumor Trial in Houston (tepotinib, tepotinib plus osimertinib)

Not yet recruiting
  • Brain Tumor
  • Houston, Texas
    M D Anderson Cancer Center
Jul 18, 2022

Colorectal Tumors Trial in Worldwide (Tepotinib, Cetuximab)

Active, not recruiting
  • Colorectal Neoplasms
  • Phoenix, Arizona
  • +66 more
Nov 19, 2021

Adenocarcinoma of the Stomach Trial in Goyang (Anti-EGFR antibody in combination with weekly paclitaxel)

Recruiting
  • Adenocarcinoma of the Stomach
  • Anti-EGFR antibody in combination with weekly paclitaxel
  • Goyang, Gyeonggi, Korea, Republic of
    National Cancer Center
Nov 29, 2022

c-MET Expression and EGFR Gene Mutation Correlation With

Completed
  • Non-small Cell Lung Cancer Metastatic
  • Non-small Cell Lung Cancer Recurrent
    • Hwasun, Korea, Republic of
      Chonnam National University Hwasun Hospital
    Aug 1, 2021

    NSCLC Trial in Shanghai (Savolitinib + Osimertinib, Pemetrexed + Cisplatin /Carboplatin)

    Recruiting
    • Non-small Cell Lung Cancer
    • Savolitinib + Osimertinib
    • Pemetrexed + Cisplatin /Carboplatin
    • Shanghai, Shanghai, China
      Shanghai Chest Hospital
    Nov 29, 2021

    Solid Tumor Trial in Pittsburgh (14C-labeled poziotinib)

    Terminated
    • Solid Tumor
    • 14C-labeled poziotinib
    • Pittsburgh, Pennsylvania
      UPMC Hillman Cancer Center
    Jun 14, 2021

    EGFR-mutant NSCLC Trial in Worldwide (EGF816, trametinib, ribociclib)

    Active, not recruiting
    • EGFR-mutant Non-small Cell Lung Cancer
    • Toronto, Ontario, Canada
    • +10 more
    Dec 5, 2022

    NSCLC Trial in Guangzhou (Avitinib Maleate, Afatinib, Crizotinib)

    Recruiting
    • Carcinoma, Non-Small-Cell Lung
    • Avitinib Maleate
    • +13 more
    • Guangzhou, Guangdong, China
      Guangdong Lung Cancer Institute, Guangdong Provincial People's H
    Dec 3, 2022

    Cerebrospinal Fluid for EGFR-mutant, ALK- and ROS1-rearranged

    Withdrawn
    • Non-Small Cell Lung Cancer
    • InVisionFirst-Lung ctDNA assay
    • Los Angeles, California
    • +2 more
    Sep 16, 2022